Effect of Poly(trehalose methacrylate) Molecular Weight and Concentration on the Stability and Viscosity of Insulin
Source abstract
Abstract
Abstract Instability to storage and shipping conditions and injection administration remain major challenges in treating chronic conditions with biopharmaceuticals. Herein, formulations of poly(trehalose methacrylate) (pTrMA) are successfully optimized to stabilize insulin without appreciably increasing viscosity. Polymers are synthesized (2400–29 200 Da), and added to insulin at different concentrations. pTrMA maintained >95% intact insulin against 250 rpm at 37 °C for 3 h with at least 10 mol. equiv. of 5.0 kDa, 7.5 mol. equiv. of 9.4 kDa, 5 mol. equiv. of 12.8 kDa, 1 mol. equiv. of 19.8 kDa, and 0.5 mol. equiv. of 29.2 kDa polymers, compared to 13.1% of insulin alone. The lowest pTrMA concentration formulations are more viscous than insulin alone, but the highest viscosity, U‐600 with 10 mol. equiv. of 5 kDa pTrMA, is only 1.43 cP at 25 °C. This data demonstrates that pTrMA is a promising low viscosity additive to stabilize the diabetes therapeutic insulin.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Protein purification and stability · Pancreatic function and diabetes · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry and Biochemistry and California NanoSystems Institute University of California, Los Angeles 607 Charles E. Young Drive East Los Angeles CA 90095‐1569 USA
Funding
National Institutes of Health
References (40)
Show source-provided references
1. 10.1038/nbt.430510.1038/nbt.4305 ↗
2. 10.1038/nrd239910.1038/nrd2399 ↗
3. 10.3389/fbioe.2020.0008910.3389/fbioe.2020.00089 ↗
4. 10.1007/s12325-019-01101-610.1007/s12325-019-01101-6 ↗
5. 10.1111/dth.1324010.1111/dth.13240 ↗
6. 10.2147/PPA.S7083410.2147/PPA.S70834 ↗
7. 10.1208/s12249-015-0288-y10.1208/s12249-015-0288-y ↗
8. 10.1016/j.addr.2011.07.00610.1016/j.addr.2011.07.006 ↗
9. 10.1007/s11095-020-02919-410.1007/s11095-020-02919-4 ↗
10. 10.1023/B:PHAM.0000008042.15988.c010.1023/B:PHAM.0000008042.15988.c0 ↗
11. 10.1007/s00726-007-0506-310.1007/s00726-007-0506-3 ↗
12. 10.1016/S0006-3495(85)83932-110.1016/S0006-3495(85)83932-1 ↗
13. 10.1002/prot.2210310.1002/prot.22103 ↗
14. 10.1016/j.xphs.2019.10.02210.1016/j.xphs.2019.10.022 ↗
15. 10.1038/nchem.157310.1038/nchem.1573 ↗
16. 10.1016/j.ijbiomac.2010.04.00310.1016/j.ijbiomac.2010.04.003 ↗
17. 10.1038/nchem.121310.1038/nchem.1213 ↗
18. 10.1016/j.actbio.2020.03.03210.1016/j.actbio.2020.03.032 ↗
19. 10.1073/pnas.151246511210.1073/pnas.1512465112 ↗
20. 10.1021/bm400304610.1021/bm4003046 ↗
21. 10.1039/C7PY00700K10.1039/C7PY00700K ↗
22. 10.1021/acs.bioconjchem.6b0065910.1021/acs.bioconjchem.6b00659 ↗
23. 10.1021/acsmacrolett.7b0097410.1021/acsmacrolett.7b00974 ↗
24. 10.1021/acs.biomac.0c0013310.1021/acs.biomac.0c00133 ↗
25. 10.1002/jps.2007910.1002/jps.20079 ↗
26. 10.1016/j.copbio.2009.10.00610.1016/j.copbio.2009.10.006 ↗
27. 10.1016/j.addr.2011.09.00810.1016/j.addr.2011.09.008 ↗
28. 10.1016/j.coche.2017.04.00110.1016/j.coche.2017.04.001 ↗
29. 10.1039/C5RA21068B10.1039/C5RA21068B ↗
30. 10.1016/j.ijpharm.2008.03.04110.1016/j.ijpharm.2008.03.041 ↗
31. 10.1136/bmj.a221810.1136/bmj.a2218 ↗
32. 10.1016/S0378-5173(96)04700-X10.1016/S0378-5173(96)04700-X ↗
33. 10.2337/diaspect.29.3.13610.2337/diaspect.29.3.136 ↗
34. 10.1177/193229681455786010.1177/1932296814557860 ↗
35. 10.3390/jcm501000510.3390/jcm5010005 ↗
36. 10.1007/978-3-642-38730-2_210.1007/978-3-642-38730-2_2 ↗
37. 10.1021/je00015a05010.1021/je00015a050 ↗
38. 10.1515/cppm-2016-003710.1515/cppm-2016-0037 ↗
39. 10.1021/bm400304610.1021/bm4003046 ↗
40. 10.1021/ma202725c10.1021/ma202725c ↗